The Journal of Nuclear Medicine | 2019
Reply: Off-Target Report on 18F-Sodium Fluoride PET/CT for Detection of Skeletal Metastases in Prostate Cancer
Abstract
1. Zacho H, Jochumsen MR, Langkilde NC, et al. No added value of 18F-sodium fluoride PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer with normal bone scintigraphy. J Nucl Med.May 30, 2019 [Epub ahead of print]. 2. Høilund-Carlsen PF, Hess S, Alavi A. Bone marrow and not bone metastases is what 21st century diagnostic imaging must focus upon when looking for skeletal metastases. J Nucl Med. 2018;59:1165. 3. Høilund-Carlsen PF, Hess S, Werner TJ, Alavi A. Cancer metastasizes to the bone marrow and not to the bone: time for a paradigm shift! Eur J Nucl Med Mol Imaging. 2018;45:893–897. 4. Langsteger W, Rezaee A, Pirich C, Beheshti M. 18F-NaF-PET/CT and 99mTc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer. Semin Nucl Med. 2016;46:491–501. 5. Löfgren J, Mortensen J, Rasmussen SN, et al. A prospective study comparing 99mTc-hydroxyethylene-diphosphonate planar bone scintigraphy and whole-body SPECT/CT with 18F-fluoride PET/CT and 18F-fluoride PET/MRI for diagnosing bone metastases. J Nucl Med. 2017;58:1778–1785. 6. Basu S, Alavi A. Bone marrow and not bone is the primary site for skeletal metastasis: critical role of [18F]fluorodeoxyglucose positron emission tomography in this setting. J Clin Oncol. 2007;25:1297. 7. Basu S, Torigian D, Alavi A. Evolving concept of imaging bone marrow metastasis in the twenty-first century: critical role of FDG-PET.Eur JNuclMedMol Imaging. 2008;35:465–471.